Initiative 18|11 explores prescription drug rebates and their impact on consumer pharmacy spend

Actuaries should account for the impact of coupons and PAPs on the health care system

Health actuaries should consider DTCPA impact when developing cost projections and setting premium rates

Measuring and understanding cost trends will be essential to addressing increasing pharmaceutical costs

A brief history of ERM modeling and what’s coming next

Predicting mortality for post-level term insurance

By understanding the drug pricing process, actuaries can help develop new payment methods in a world of rising drug costs

How much money is spent on prescription drugs in the United States

How the process of drug development works and impacts overall health care benefit cost projections

A look at enterprise and financial risk strategy development and support